Browsing: Lillys

The FDA clearance follows European ⁠approval for the test in May. See all topics

Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>

Eli Lilly and Company (NYSE:LLY) cleared a notable regulatory hurdle on August 10, when Britain’s drug regulator authorized the company’s oral GLP-1 drug orforglipron, becoming the first country in Europe to approve the pill. Shares of LLY increased more than 2% in response to the announcement, a modest but insightful reaction for a company whose…

Eli Lilly’s Foundayo is the second oral weight-loss pill to be approved in Europe, after U.K. approval. On Monday, the U.K.’s Medicines and Healthcare products regulatory agency announced approval of orforglipron, to be marketed as Foundayo, for helping patients lose weight and manage type 2 diabetes. But there’s a catch for British patients: the drug…

Eli Lilly’s new weight-loss pill orforglipron – brand named Foundayo – has been authorised today (10 August) by the Medicines and Healthcare products Regulatory Agency (MHRA)

The British medicines regulator has approved Eli Lilly’s Foundayo pill, marking a first in Europe for weight management and type 2 diabetes treatment

Eli Lilly’s Foundayo (orforglipron) has secured UK regulatory approval for weight management and type 2 diabetes, making the UK the first European country to authorise the once-daily GLP-1 tablet

Eli Lilly (NYSE: LLY) is already the leader in the weight-loss market thanks to Zepbound, the best-selling medication in this space. However, the drugmaker has been making headlines with its next-gen anti-obesity medicine, retatrutide. Eli Lilly recently announced that it will request approval from the U.S. Food and Drug Administration for retatrutide in the first…

Eli Lilly (NYSE:LLY | LLY Price Prediction) opened Wednesday’s session with a blowout second-quarter earnings report, sending shares sharply higher and cementing the drugmaker’s status as the only pharmaceutical company trading above a $1 trillion market cap. On a CNBC segment breaking down the release, anchor Joe Kernen walked viewers through the headline figures that…

Aug 5 (Reuters) – Sales of Eli Lilly’s Zepbound and Mounjaro injectable weight-loss and diabetes drugs soared during the second quarter, easily beating Wall Street estimates and widening the gap with Danish rival Novo Nordisk